Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

Timothy Garvey, W.; L. Batterham, Rachel; Bhatta, Meena; Buscemi, Silvio; Christensen, Louise; P. Frías, Juan; Jódar, Esteban; Kandler, Kristian; Rigas, Georgia; A. Wadden, Thomas; Wharton, Sean; STEP 5 Study Group, the

doi:10.1038/s41591-022-02026-4

Public

Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial

Published in Nature Medicine • Oct 1, 2022

Authors:

W. Timothy Garvey

Rachel L. Batterham

Meena Bhatta

Abstract

Abstract The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes. The co-primary en...

Subject

Semaglutide

Medicine

Placebo

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!